Bioscience

ImmuneRegen BioSciences announces collaboration with the of the Radboud University Nijmegen Medical Centre

April 27, 2010

By Flinn Foundation

[Source: MARKETWIRE] – ImmuneRegen BioSciences Inc.(R), a wholly owned subsidiary of IR Biosciences Holdings Inc., today announced a collaboration and research agreement with the Department of Tumor Immunology of the Radboud University Nijmegen Medical Centre (RUMC), in the Netherlands to commence studies utilizing ImmuneRegen’s Homspera. Under the agreement top cancer vaccine experts at RUMC will perform exploratory studies on Homspera relating to its adjuvant and immunomodulatory properties for potential application in experimental cancer vaccines and immunotherapy for cancer.

For more information: ImmuneRegen BioSciences(R) Announces Collaboration With the Department of Tumor Immunology of the Radboud University Nijmegen Medical Centre, the Netherlands